NCT07726563 Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
| NCT ID | NCT07726563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Amyotrophic Lateral Sclerosis (ALS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-05-19 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-05-19 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.
Eligibility Criteria
Inclusion Criteria: * ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma * Agree to receive plasmapheresis treatment * Agree to participate in the study and receive serial examinations Exclusion Criteria: * Under permanent ventilator support * Cannot receive plasmapheresis treatment or serial examinations * Under pregnancy * Blood fibrinogen level below 50 mg/dl * Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07726563 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Amyotrophic Lateral Sclerosis (ALS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07726563 currently recruiting?
Yes, NCT07726563 is actively recruiting participants. Contact the research team at milikai@ntuh.gov.tw for enrollment information.
Where is the NCT07726563 trial being conducted?
This trial is being conducted at Taipei City, Taiwan.
Who is sponsoring the NCT07726563 clinical trial?
NCT07726563 is sponsored by National Taiwan University Hospital. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.